Sign In
Buy MNKD
$4.13
+0.240 (+6.17%)
At Close: Jul 24, 2026
Implied Volatility Surging for MannKind (MNKD) Stock Options
12:49pm, Thursday, 18'th Jun 2020
Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
12:00am, Thursday, 18'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 17)
Adverum Biotechnologies Inc...
MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference
09:00pm, Wednesday, 17'th Jun 2020
MannKind Corporation (MNKD) announced today that it will be featured in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June
Why MannKind Shares Are Soaring Again Today | The Motley Fool
03:41pm, Wednesday, 17'th Jun 2020
Momentum is still in swing from the biotech's recent presentations.
Why MannKind Stock Is Crushing It Today | The Motley Fool
08:07pm, Monday, 15'th Jun 2020
Investors liked the biotech's presentations at a major diabetes conference.
WESTLAKE VILLAGE, Calif., June 15, 2020 -- MannKind Corporation (Nasdaq: MNKD) announced that new data from clinical studies of Afrezza® (insulin human) Inhalation Powder was.
Investigator-Initiated Study Shows Switching to Afrezza® Improves Glucose Control with No Additional Hypoglycemia in T2DM
04:00pm, Saturday, 13'th Jun 2020
MannKind Corporation (MNKD) announced that data from a new clinical study of Afrezza® (insulin human) Inhalation Powder will be presented at the American Diabetes Association’s 80th Scientific Sess
MannKind: Stone Age Technology Isn't A Solution For Modern Day Medical Needs (NASDAQ:MNKD)
12:52pm, Saturday, 13'th Jun 2020
Readers will read about the updates for the Afrezza issues. I will discuss the impact of the hidden financial issue disclosed in the recent quarterly report. R
Investigator-Initiated Study Shows Switching to Afrezza® Improves Glucose Control with No Additional Hypoglycemia in T2DM
12:00am, Saturday, 13'th Jun 2020
WESTLAKE VILLAGE, Calif., June 13, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that data from a new clinical study of Afrezza®...
Hedge Funds Never Been Less Bullish On MannKind Corporation (MNKD)
05:10pm, Friday, 05'th Jun 2020
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
Introducing MannKind (NASDAQ:MNKD), The Stock That Tanked 94%
03:12pm, Monday, 25'th May 2020
MannKind Corporation (NASDAQ:MNKD) shareholders should be happy to see the share price up 18% in the last week. But...
MannKind (MNKD) Stock Could Nearly Double in the Next Year, Says Analyst
12:44am, Wednesday, 20'th May 2020
It has been a rough five years for investors of diabetes-focused biotech MannKind (MNKD). Over the period, shares of the company have declined by 94%. However, according to H.C. Wainwright analyst Or
Coronavirus puts top executives’ pay in the spotlight
03:31am, Monday, 18'th May 2020
Cuts for some CEOs but no change for others — and a split between sectors
